Agreements (Details 2) (Amgen, USD $)	1 Months Ended	3 Months Ended							1 Months Ended
	Sep. 30, 2000 Right-to-test agreement Undisclosed Target	Nov. 30, 2009 Right-to-test agreement Undisclosed Target item	Jun. 30, 2012 Development and Commercialization License Development milestones Phase II clinical trial	Sep. 30, 2000 Development and Commercialization License Undisclosed Target	Sep. 30, 2000 Development and Commercialization License Undisclosed Target Maximum	Sep. 30, 2000 Development and Commercialization License Undisclosed Target Development milestones	Sep. 30, 2000 Development and Commercialization License Undisclosed Target Regulatory milestones	Sep. 30, 2000 Development and Commercialization License Undisclosed Target Sales milestones	Nov. 30, 2011 Development and Commercialization License Undisclosed Target IND application effective item
Collaborative Agreements disclosures
Term of agreement	10 years
Payments received under collaboration agreement	$ 5,000,000
License exercise fee, per license				1,000,000
Potential milestone payments receivable			3,000,000		34,000,000	9,000,000	20,000,000	5,000,000
Number of development and commercialization licenses taken		2
Fee received per license		$ 1,000,000							$ 1,000,000
Number of compounds under development and commercialization licenses									2
Number of milestone payments									2